Compagnie Lombard Odier SCmA Buys 22,663 Shares of Johnson & Johnson $JNJ

Compagnie Lombard Odier SCmA lifted its stake in Johnson & Johnson (NYSE:JNJ) by 7.0% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 346,241 shares of the company’s stock after buying an additional 22,663 shares during the quarter. Compagnie Lombard Odier SCmA’s holdings in Johnson & Johnson were worth $64,200,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wesbanco Bank Inc. raised its stake in Johnson & Johnson by 0.4% during the 3rd quarter. Wesbanco Bank Inc. now owns 149,621 shares of the company’s stock worth $27,743,000 after acquiring an additional 524 shares during the period. BridgePort Financial Solutions LLC raised its position in shares of Johnson & Johnson by 66.5% during the 3rd quarter. BridgePort Financial Solutions LLC now owns 4,910 shares of the company’s stock valued at $910,000 after purchasing an additional 1,961 shares during the period. Wealthfront Advisers LLC lifted its stake in shares of Johnson & Johnson by 9.6% during the 3rd quarter. Wealthfront Advisers LLC now owns 314,087 shares of the company’s stock valued at $58,238,000 after buying an additional 27,625 shares in the last quarter. Summit Asset Management LLC boosted its holdings in Johnson & Johnson by 2.6% in the 3rd quarter. Summit Asset Management LLC now owns 14,749 shares of the company’s stock worth $2,735,000 after buying an additional 374 shares during the period. Finally, Delap Wealth Advisory LLC purchased a new stake in Johnson & Johnson in the 3rd quarter worth $262,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on JNJ shares. Guggenheim upped their price objective on Johnson & Johnson from $227.00 to $240.00 and gave the stock a “buy” rating in a research note on Friday, January 23rd. UBS Group restated a “buy” rating on shares of Johnson & Johnson in a research note on Monday, January 5th. Johnson Rice set a $190.00 price objective on shares of Johnson & Johnson and gave the company a “hold” rating in a report on Wednesday, October 22nd. BMO Capital Markets reissued an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. Finally, Leerink Partners raised their target price on shares of Johnson & Johnson from $201.00 to $232.00 and gave the company a “market perform” rating in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $233.73.

Johnson & Johnson Price Performance

JNJ stock opened at $238.62 on Tuesday. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 52 week low of $141.50 and a 52 week high of $240.93. The company has a fifty day simple moving average of $214.20 and a two-hundred day simple moving average of $194.70. The firm has a market capitalization of $574.90 billion, a P/E ratio of 21.59, a price-to-earnings-growth ratio of 2.33 and a beta of 0.35.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 21st. The company reported $2.46 earnings per share for the quarter, hitting the consensus estimate of $2.46. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The company had revenue of $24.56 billion for the quarter, compared to analysts’ expectations of $24.14 billion. During the same period in the previous year, the firm posted $2.04 earnings per share. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. Analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 47.06%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.